Open AccessExploration of predictive biomarkers for postoperative recurrence of stage II / III colorectal cancer using genomic sequencing
Author(s) -
Kishigami Fumishi,
Tanaka Yosuke,
Yamamoto Yoko,
Ueno Toshihide,
Kojima Shinya,
Sato Kazuhito,
Inoue Satoshi,
Sugaya Saori,
Ishihara Soichiro,
Mano Hiroyuki,
Kawazu Masahito
Publication year - 2022
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.4710
Subject(s) - colorectal cancer , medicine , stage (stratigraphy) , cancer , oncology , biology , paleontology
Postoperative recurrence of colorectal cancer (CRC) eventually leads to therapeutic failure; therefore, treatment strategies based on accurate prediction of recurrence are urgently required. To identify biomarkers that can predict treatment outcomes, we compared the mutational profiles of surgically resected specimens from patients with recurrent cancer with those from patients with non‐recurrent cancer. Target sequencing, whole‐exome sequencing (WES), or whole‐genome sequencing (WGS) was performed on 89 and 58 tumors from recurrent and non‐recurrent cases, respectively. WGS revealed the driver mutations that were not detected with target sequencing or WES, including the structural variations affecting ZFP36L2 . Loss of function of ZFP36L2 was frequently observed in primary tumors from recurrent cases. Furthermore, the recurrence‐free survival of patients with loss of function of ZFP36L2 was significantly shorter relative to patients with no loss of ZFP36L2 function. In summary, the study demonstrated that detailed genomic analysis could help improve precision medicine for CRC.